Ketamine may be quick, effective treatment for untreatable depression - Michelle Castillo
The anesthetic agent ketamine continues to show tantalizing promise in psychiatric disorders, with results from new studies in intractable depression and obsessive-compulsive disorder. In a 72-patient randomized trial involving patients with major depression who had not responded to standard therapies, mean scores on the Montgomery-Asberg Depression Rating Scale (MADRS) fell by half 1 day after an intravenous infusion with ketamine, significantly more than in an "active placebo" group receiving the benzodiazepine agent midazolam. The ketamine group continued to show significantly greater improvement for the next two days relative to the controls, according to James W. Murrough, MD, of the Icahn School of Medicine at Mount Sinai. -Dr. James Murrough, Assistant Professor, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai
Learn more
Mount Sinai Launches Institute for Regenerative Medicine
Apr 24, 2023 View All Press Releases
